Interest in BCL-2 inhibition has increased, especially for patients with the t(11;14) translocation, a cytogenetic marker found in over 50% of individuals with AL amyloidosis and PCL, which is linked to and promotes BCL-2 activation (11, 12). The gene discussed is BCL2; the disease is AL amyloidosis.